By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ChemoCentryx, Inc. 

850 Maude Avenue

Mountain View  California  94043  U.S.A.
Phone: 650-210-2900 Fax: 650-210-2910


"People Deserve Better Medicine and not just a longer life---a better life."

Located in the heart of the Silicon Valley, ChemoCentyx is a biotechnology company that focuses on chronic kidney diseases, immuno-oncology, and other autoimmune and inflammatory diseases.

Our vision can only be accomplished through talented people who share our culture and values.

We have created a corporate culture of scientific innovation, placing emphasis on hard work, honesty, and industry-leading technology in a fun, team-oriented atmosphere. We treat each other with respect at all times. We expect employees to add value as individuals and as team members. We work hard to nurture this environment.

As a late clinical development stage company, we are focused on a pipeline that discovers, develops and commercializes orally-administered therapeutics.

"ChemoCentryx: Great Science, Great Medicine"

Key Statistics

Ownership: Public

Web Site: ChemoCentryx
Employees: 60
Symbol: CCXI


Company News
ChemoCentryx (CCXI) Reports Second Quarter 2017 Financial Results And Recent Highlights 8/9/2017 1:36:04 PM
ChemoCentryx (CCXI) To Hold Second Quarter 2017 Financial Results Conference Call On Tuesday, August 8, 2017 7/26/2017 8:55:49 AM
ChemoCentryx (CCXI) Release: Oral Presentations At ERA-EDTA Congress Highlight Fourth Potential Indication For Avacopan And Potential For CCR2 Inhibition In Focal Segmental Glomerulosclerosis (FSGS) 6/6/2017 8:21:48 AM
ChemoCentryx (CCXI) Granted EU Orphan Drug Designation For Avacopan In The Treatment Of Debilitating Kidney Disease C3 Glomerulopathy (C3G) 5/23/2017 10:19:44 AM
ChemoCentryx (CCXI) Reports First Quarter 2017 Financial Results 5/11/2017 1:10:03 PM
ChemoCentryx (CCXI) To Hold First Quarter 2017 Financial Results Conference Call On Wednesday, May 10, 2017 4/27/2017 9:03:50 AM
Bay Area's ChemoCentryx (CCXI) Inks $85 Million Deal With Vifor Pharma for Lead Product Candidate 5/11/2016 7:04:38 AM
Vifor Pharma Licenses Rights To Commercialize ChemoCentryx, Inc. (CCXI)’s Orally-Administered Complement 5aR Inhibitor CCX168 For Orphan And Rare Renal Diseases In Europe And Certain Other Major Markets 5/10/2016 11:24:26 AM
ChemoCentryx, Inc. (CCXI) Reports First Quarter 2016 Financial Results and Provides Corporate Update 5/10/2016 8:23:29 AM
ChemoCentryx, Inc. (CCXI) Announces Positive Results In Phase II ANCA-Associated Vasculitis CLEAR Trial Of Orally Administered Complement 5a Receptor Inhibitor CCX168 1/6/2016 10:38:33 AM